glicitina

Glycitin: A Comprehensive Encyclopedic Reference

1. Identity and Chemical Characterization

1.1 Nomenclature and Structure

Glycitin (glycitein 7-O-glucoside) is an isoflavone found in soy, and remains to various degrees in soy products like tofu, soymilk, and soy sauce. Glycitin is defined as glycitein-7-O-glucoside, a chemical structure that belongs to the class of isoflavonoids. Its aglycone form — the compound produced after removal of the sugar moiety — is called glycitein, with the systematic name 4′,7-dihydroxy-6-methoxyisoflavone. Glycitein (4′,7-dihydroxy-6-methoxyisoflavone) accounts for 5–10% of the total isoflavones in soy food products.

Glycitein, a significant constituent of the soy isoflavone family, has become a focal point of investigation in nutritional and pharmaceutical sciences owing to its unique structural characteristics and diverse bioactivities. In contrast to other prominent soy isoflavones such as daidzein, genistein, formononetin, and biochanin A, glycitein features a unique methoxy substitution at the C-6 position, resulting in significantly different physicochemical properties and bioavailability characteristics. This C-6 methoxy substitution — a structural distinction from other soy isoflavones — enhances lipophilicity, metabolic stability, and tissue-specific bioactivity, enabling superior antioxidant and anti-inflammatory effects.

Isoflavones are flavonoids in which ring B of the flavone molecule is attached to carbon 3 of the heterocycle. Attending to their functional groups, isoflavones can be classified into four subgroups: aglycones (daidzein, genistein, glycitein), glucosides (daidzin, genistin, glycitin), malonyl glucosides (malonyl daidzin, malonyl genistin, malonyl glycitin), and acetyl glucosides (acetyl daidzin, acetyl genistin, and acetyl glycitin). In soybeans, glycitin is the glucoside form of glycitein, and it can also exist as malonylglycitin (malonylated) and acetylglycitin (acetylated). This product may be further malonylated to malonylglycitin.

1.2 Botanical Sources

Isoflavones are fairly widely distributed within the plant kingdom, although they are found predominantly in members of the Leguminosae family. The estrogenic isoflavones (genistein, biochanin, formononetin, daidzein, glycitein) follow this general rule in being largely restricted to the genus Leguminosae. Most legumes investigated have been found to contain at least detectable levels of one or more of these five estrogenic isoflavones, but the richest sources are the legumes — soya, lentils, chickpeas, fenugreek, clovers, alfalfa, and various varieties of beans.

Three different isoflavonoids have been described in soybean and soy products — two isoflavones, daidzein and genistein, and a methoxyisoflavone, glycitein — found in a typical ratio of 45:45:10. The content percentage of genistein, daidzein, and glycitein was about 50%, 40%, and 10% from total isoflavone profiles, respectively.

Glycitein is a major isoflavone of soy germ, which is used as a functional ingredient to enrich foods with isoflavones as well as a component of soy supplements. Within the soybean plant itself, isoflavone concentrations vary by plant tissue and variety. An HPLC/UV-vis method was applied for the determination of isoflavone aglycons and glycosides in roots, stems, leaves, and soy pods of soy plants and in soybeans of five varieties. The highest isoflavone concentrations were found in roots (12.5 μg g⁻¹ dry weight), while the amounts were about 3–1100 μg g⁻¹ fresh weight in different varieties of soybeans.

1.3 Common Forms and Preparations

In soybeans, there are 12 main isoflavones such as free aglycones (daidzein, genistein, and glycitein), their respective glucosides (daidzin, genistin, and glycitin), acetyl glucosides (acetyldaidzin, acetylgenistin, and acetylglycitin), and malonyl glucosides (malonyldaidzin, malonylgenistin, and malonylglycitin).

The glycosidic form (either alone or in the malonyl or acetyl forms) is water-soluble and is the predominant form for the isoflavones in the plant, to facilitate transport and storage. The glycosidic form also provides enhanced stability to degradative factors such as heat, oxidation, and ultraviolet irradiation.

Soy-derived foods containing glycitin include tofu, soymilk, miso, natto, tempeh, and soy sauce, each with differing glycitin levels depending on processing. Fermentation (to obtain miso and tempeh) and heat treatment can induce the hydrolysis of glycosides to convert them to aglycones, which are highly heat resistant. When compared to commercial foods, the isoflavone content was found to be 20, 2.6, 4.5, and 9.8 times lower in "homemade" soy juice, tofu, tempeh, and miso, respectively.

As a dietary supplement, glycitin and the related soy isoflavone mixture are available in capsule and tablet forms, often standardized for total isoflavone content. Novel strategies to overcome bioavailability challenges include microbial biotransformation, nano-formulations, and microencapsulation, which play a role in stabilizing glycitein for functional foods such as fermented dairy and beverages.

2. Traditional and Historical Use

Glycitin as an isolated, chemically characterized compound was not known until the twentieth century. However, its primary natural vehicle — the soybean (Glycine max) — has millennia of documented use across East Asia. Soybean seeds are not directly consumed by humans, but only as various products obtained by fermentation, soaking, filtration, frying, or boiling. Soy products have been traditionally consumed in Asian countries.

In East Asian cuisines, soybeans have been eaten for millennia. Tofu in China around 2,000 years ago, miso in Japan, and natto later on — the glycitein content varied by fermentation times and bean varieties. Research has discovered that in Asian countries like Japan, where the traditional diet is high in soy protein, very few women complain about menopausal symptoms — for example, only 9% of Japanese women complain about hot flashes. In addition, younger women have fewer menstrual periods per year, and occurrences of some cancers (breast and endometrial), heart disease, and other chronic diseases are very low.

The traditional framework for understanding these benefits did not use the concept of "isoflavone" or "glycitin," but rather attributed effects to the whole soy food. Soy isoflavones are compounds found in soybean and soybean products. They have been reported to possess numerous physiological properties, such as antitumor, anti-menopausal (female) osteoporosis, and anti-aging effects. They have also been reported to improve learning and memory skills in menopausal women and aid in the prevention and treatment of heart disease, diabetes, and Kawasaki disease.

On the scientific history of isolation: glycitein was first isolated in the mid-20th century as part of a broader search into soy isoflavones. Early chemists in Japan and the U.S. cataloged daidzein and genistein and then later "glycitein" in 1965, noticing its unique side-chain methylation. In the 1970s and 1980s, epidemiological studies on Asian populations linked higher soy intake with lower rates of menopausal symptoms and certain cancers, prompting lab research into glycitein's estrogen receptor interactions. The broader context of phytoestrogen research, of which glycitin/glycitein studies are a part, accelerated significantly in the latter decades of the twentieth century as epidemiological differences between Asian and Western populations attracted scientific scrutiny.

3. Key Constituents, Chemistry, and Mechanisms of Action

3.1 Relationship Between Glycitin and Glycitein

It is important to distinguish between glycitin (the glucoside) and glycitein (the aglycone), as the two terms appear in the scientific literature with sometimes overlapping usage. Like other isoflavonoids, glycitein is synthesized as a glycoside conjugate to a monosaccharide (typically glucose). The glycoside is hydrolyzed during digestion to the biologically active free isoflavonoid. Glycitin can be transformed to glycitein by human intestinal flora by the action of beta-glucosidases.

Glycitein is synthesized from phenylalanine, similarly to other isoflavonoids. The biosynthesis involves 8 steps, resulting in free glycitein; a subsequent glucosyltransferase-catalyzed reaction results in the corresponding glucoside, glycitin.

3.2 Estrogenic (Phytoestrogenic) Activity

Glycitein is an O-methylated isoflavone which accounts for 5–10% of the total isoflavones in soy food products. Glycitein is a phytoestrogen with weak estrogenic activity, comparable to that of the other soy isoflavones.

Soy isoflavones are frequently referred to as weak estrogens, and depending upon the specific circumstance, they can act as agonists, partial agonists, or antagonists to endogenous estrogens (such as estradiol) and xenoestrogens (including phytoestrogens) at estrogen receptors. Isoflavones are diphenolic compounds with a chemical structure similar to estrogen that bind to both estrogen receptors alpha (ERα) and beta (ERβ), and for this reason are commonly referred to as phytoestrogens. Isoflavones exhibit estrogen-like properties but bind more weakly to ERs than 17β-estradiol (E2), which is the primary physiologic estrogen.

Specifically for glycitein, a 1999 competitive binding study measured that the concentrations required to displace 50% of ³H-estradiol at 5 nM were 1.15 nM DES, 1.09 nM 17β-estradiol, 0.22 μM genistein, 4.00 μM daidzein, and 3.94 μM glycitein. These data indicated that glycitein has weak estrogenic activity, comparable to that of the other soy isoflavones but much lower than that of DES and 17β-estradiol.

It binds to the human estrogen receptor (as do other isoflavonoids), and while it does so with lower affinity than other isoflavonoids, it is thought to be overall more potent as an estrogen receptor agonist due to its high bioavailability.

3.3 Antioxidant Activity

Glycitin and its aglycone glycitein are recognized for their ability to scavenge reactive oxygen species (ROS). In vitro scavenging effects of glycitein on three types of reactive oxygen species confirmed its antioxidant properties. Furthermore, transgenic C. elegans fed with glycitein exhibited reduced formation of β-amyloid. These findings suggest that glycitein may suppress Aβ toxicity through combined antioxidative activity and inhibition of Aβ deposition.

3.4 Anti-inflammatory Mechanisms

In preclinical (cell-based) research, glycitin antagonized NF-κB pathway activity. In addition, glycitin alleviated TNF-α-induced metabolic disorders, extracellular matrix degradation, oxidative stress, inflammation responses, and mitochondrial damage.

In a mouse model of lipopolysaccharide-induced acute lung injury, glycitin obviously alleviated the lung injury induced by LPS, as indicated by histopathological changes, the wet/dry weight ratio, and myeloperoxidase (MPO) activity. In addition, glycitin could dose-dependently decrease the expressions of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α.

3.5 Signaling Pathways

Using network pharmacology, glycitein's polypharmacological actions span NF-κB, Nrf2, and MAPK pathways, linking its multi-target effects to clinical applications in cancer chemoprevention, cardiovascular protection, and neuroprotection.

In skin fibroblasts, matrix metalloproteinase-1 collagenase was decreased in the media after 24-h incubation with glycitin, and the synthesis of transforming growth factor-beta (TGF-β) mRNA increased approximately twofold in cells following glycitin treatment. Phosphorylation of Smad2 and Smad3 increased after 1 hour of glycitin treatment, and phosphorylation continued for 24 h. Furthermore, the phosphorylated form of AKT was increased in glycitin-treated cells after 3 h and remained higher for 24 h.

In bone marrow stem cells, glycitin regulated osteoblasts from bone marrow stem cells (BMSCs) through transforming growth factor (TGF)-β or protein kinase B (AKT) signaling pathways. Administration of glycitin increased cell proliferation and promoted osteoblast formation from BMSCs.

In a myocardial ischemia/reperfusion model, glycitin demonstrated anti-inflammatory, anti-oxidative, and anti-osteoporosis effects. Investigation of the underlying molecular mechanisms involved analysis of the PI3K/Akt/NF-κB pathway modulation, with cardioprotective outcomes measured by levels of MDA, GSH-Px, LDH, CK, TNF-α, IL-6, and SOD.

4. Scientific Evidence by Area of Use

4.1 Bone Health and Osteoporosis

Daidzein, genistein, glycitin, and glycosides of daidzein and genistein namely daidzin and genistin are constituents of soybean (Glycine max, Leguminosae) and are effective antiosteoporotic agents. Soy isoflavones, especially in the form of aglycones (daidzein, genistein, and glycitein) and glucosides (daidzin, genistein, and glycitin), are effective in bone health by reducing bone resorption and stimulating bone formation.

Preclinical evidence: Research has shown that isolated glycitin from fermented black soybean had strong anti-osteoporosis activity. Glycitin also promoted bone mesenchymal stem cell (BMSC) proliferation and cell formation by inhibiting the expression of TGF-β and protein kinase B. An in vitro experiment showed that glycitein not only effectively inhibited osteoclast production, but also inhibited the differentiation of marrow stromal cells (MSCs) into adipocytes mediated by PPARγ, increasing the number of osteoblasts and the concentration of serum osteocalcin, which was helpful in preventing steroid-induced osteonecrosis.

Clinical evidence (mixed isoflavone products): In a randomized, double-blind, placebo-controlled clinical trial in Japan, it was shown that taking 100 mg of isoflavone supplements per day (20.9% daidzein, 4.5% genistein, 10.5% glycitein) increased BMD and BMI. However, a multicenter, randomized, double-blind, placebo-controlled study showed that 120 mg of hypocotyl soy isoflavones over 24 months reduced whole-body bone resorption but did not affect BMD in key fracture sites. These clinical trials examined mixed isoflavone preparations and cannot be attributed to glycitin in isolation. There are indicators from a couple of recent in vitro studies that glycitein may be protective of bone. Most glycitein research has focused on determining how to detect the compound, and its estrogenicity and metabolism.

Evidence strength: Preclinical evidence (cell-based and animal studies) supports bone-protective effects via multiple mechanisms; however, no clinical trials have specifically isolated glycitin as a single intervention for bone health. Clinical data derive from mixed soy isoflavone preparations, making attribution to glycitin alone impossible at this time.

4.2 Dermal and Skin Health / Wound Healing

Glycitin is a soy isoflavone that exhibits antioxidant, antiallergic, and anti-osteoporosis activities. In a cell-based study, treatment of primary dermal fibroblasts with glycitin increased cell proliferation and migration. In addition, treatment with 20 μM glycitin for 24 h induced the synthesis of collagen type I and type III at both the mRNA and protein levels. Fibronectin was also increased by 20% after treatment.

Effects of glycitin include human dermal fibroblast cell proliferation and migration via TGF-β signaling; glycitin treatment produces anti-photoaging effects such as collagen type I and collagen type III increase at both the mRNA and protein levels. Other noted effects included decreased elastase and decreased β-galactosidase activation.

In an animal model of wound healing, mice treated with a 1:1 ratio of TMF and glycitin showed faster wound closure, regeneration, and scar reduction than even the positive control drug. These data indicate that two isoflavones, TMF and glycitin, act synergistically to promote wound healing and anti-scarring activity and could potentially be developed together as a bioactive therapeutic for wound treatment.

Evidence strength: Current evidence for dermal/skin applications is preliminary and based on in vitro (primary human fibroblast) and animal model data. No human clinical trials specific to glycitin's topical or oral skin effects have been identified in the peer-reviewed literature.

4.3 Neuroprotection and Neurological Health

Transgenic C. elegans that express human beta-amyloid (Aβ) were fed with soy-derived isoflavones genistein, daidzein, and glycitein (100 μg/ml) and then examined for Aβ-induced paralysis and the levels of reactive oxygen species. Among the three compounds tested, only glycitein alleviated Aβ expression-induced paralysis in the transgenic C. elegans. This activity of glycitein correlated with a reduced level of hydrogen peroxide in the transgenic C. elegans.

The assumption that the protective effect by glycitein against Aβ toxicity might not be mediated by its action on the estrogen receptor is supported by the observation that genistein, with the strongest estrogenic activity among soy isoflavones, did not offer protection against Aβ-toxicity. This suggests that glycitein's neuroprotective mechanism is distinct from simple estrogen receptor activation and may instead depend primarily on its antioxidant activity.

A rat epilepsy model study examined the neuroprotective impact of glycitin on memory impairment in a pentylenetetrazol-induced chronic epileptic rat model, providing insights into hippocampal histology, oxidative stress, and inflammation.

Evidence strength: Preliminary, non-clinical. Neuroprotective effects have been demonstrated in invertebrate (C. elegans) and rodent models only. No human clinical trials investigating glycitin's effects on neurological outcomes have been identified.

4.4 Cardiovascular Health

Soy isoflavones including genistein, daidzein, and glycitein have been found to exhibit chemopreventive, cardioprotective, and anti-osteoporosis effects. In terms of vascular smooth muscle, one preclinical study showed that genistein, daidzein, and glycitein inhibit growth and DNA synthesis of aortic smooth muscle cells from stroke-prone spontaneously hypertensive rats.

A Springer Nature study investigated the cardioprotective effects of glycitin against myocardial ischemia/reperfusion injury in animal models. This study aimed to investigate the cardioprotective effects of glycitin against MI/R-induced myocardial injury and to elucidate its underlying molecular mechanisms. The levels of malondialdehyde (MDA), glutathione peroxidase (GSH-Px), lactate dehydrogenase (LDH), creatine kinase (CK), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and superoxide dismutase (SOD) in cardiac tissue and serum were quantified using ELISA.

Evidence strength: Preclinical only. No dedicated clinical trials have been found that test glycitin as a standalone cardiovascular intervention in humans. Broader soy isoflavone literature provides context but cannot isolate the contribution of glycitin specifically.

4.5 Anti-Cancer / Chemopreventive Activity

All tested soy isoflavone aglycones (genistein, daidzein, glycitein) and glucosides (genistin, daidzin, glycitin) markedly reduced motility of MDA-MB-231 cells, a highly invasive breast cancer cell line, in an in vitro experiment. However, only genistein and daidzein inhibited constitutively active NF-κB and AP-1 and suppressed secretion of uPA from breast cancer cells. Together, these results suggest that dietary soy isoflavones inhibit adhesion and motility of highly invasive breast cancer cells by distinct signaling pathways.

In studies on human breast carcinoma SKBR-3 cells: cell proliferation studies on the dietary phytoestrogen glycitein against human breast carcinoma SKBR-3 cells showed that glycitein exhibits biphasic regulation. At concentrations of less than 10 mg/mL, cells respond to glycitein by increasing cell growth and de novo DNA synthesis, whereas the addition of glycitein at concentrations greater than 30 mg/mL significantly inhibited cell growth and DNA synthesis in a dose-dependent manner. Cells treated with 60 mg/mL of glycitein did not regain normal growth after treatment was stopped.

Isoflavone metabolites including glycitein inhibit LPS-induced inflammatory reactions in brain microglia. The anti-inflammatory effects of glycitein have also been reported in peripheral systems.

Evidence strength: Preliminary; in vitro only for glycitin/glycitein specifically. The biphasic dose-response observed in cell culture studies is a recognized limitation of translating in vitro findings to human physiology. No human clinical trials targeting glycitin's anticancer properties have been reported.

4.6 Intervertebral Disc Degeneration

Glycitin is a natural isoflavone extracted from legumes. Previous studies have found that it is anti-inflammatory and promotes wound repair. However, the role of glycitin in intervertebral disc degeneration (IVDD) had not been previously elucidated. Research found that glycitin antagonized the NF-κB pathway activity. In addition, glycitin alleviated TNF-α-induced metabolic disorders, extracellular matrix degradation, oxidative stress, inflammation responses, and mitochondrial damage. In an in vivo experimental study, glycitin attenuated IVDD and alleviated the degenerative phenotype of IVDD.

Evidence strength: Preclinical (in vitro and animal). No human studies specific to glycitin and disc degeneration have been published.

4.7 Estrogenic / Menopausal Effects

The key animal study establishing glycitein's estrogenic activity used a uterotrophic assay. Glycitein was isolated from soy germ to 99% purity. Weaning female B6D2F1 mice were dosed with glycitein (3 mg/day), genistein (3 mg/day), and diethylstilbestrol (DES) (0.03 μg/day) in 5% Tween 80 by gavage for 4 days. A control group received an equal volume of 5% Tween 80 solution daily. The uterine weight increased 150% with glycitein (p < 0.001), 50% with genistein (p < 0.001), and 60% with DES (p < 0.001) compared with the control group.

Soy isoflavones can act as agonists, partial agonists, or antagonists to endogenous estrogens at estrogen receptors. They are not especially potent, however, and activity varies by tissue concentration, cell type, hormone receptor type, and stage of differentiation. In addition to their estrogen receptor activity, isoflavones may also interfere with steroid metabolism by inhibiting aromatase, hydroxysteroid dehydrogenase, and steroid α-reductase.

Evidence strength: Estrogenic activity of glycitein/glycitin has been demonstrated in animal bioassays. Clinical evidence for menopausal symptom relief derives from mixed soy isoflavone supplementation studies rather than from glycitin-specific trials, making independent attribution of effect to glycitin impossible on current evidence.

5. Body Systems and Health Areas Associated with Glycitin

• Skeletal system: The mechanisms of glycitin in anti-osteoporosis and prevention of osteonecrosis were mainly related to its selective regulation of estrogen receptors and inhibition of osteoclast differentiation and promotion of osteoblast activity.
• Integumentary system (skin): Effects of glycitin include human dermal fibroblast cell proliferation and migration via TGF-β signaling; glycitin treatment produces anti-photoaging effects such as collagen type I and collagen type III increase at both the mRNA and protein levels. Other noted effects include decreased elastase and decreased β-galactosidase activation.
• Central nervous system: Preclinical evidence for protection against beta-amyloid toxicity, reduced oxidative stress in neural tissues, and potential neuroprotective effects mediated via antioxidant mechanisms independent of estrogen receptor binding.
• Cardiovascular system: Preclinical data indicating reduction of ischemia-reperfusion injury markers via PI3K/Akt/NF-κB pathway and inhibition of smooth muscle cell proliferation.
• Musculoskeletal system (disc): Animal and cell-based evidence of protection against intervertebral disc degeneration through anti-inflammatory and antioxidant mechanisms.
• Endocrine / reproductive system: Binding to estrogen receptors ERα and ERβ; phytoestrogenic activity demonstrated in mouse uterotrophic assays.
• Immune system: Inhibition of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and suppression of NF-κB, MAPK, and AP-1 signaling pathways in preclinical models.
• Cancer biology (in vitro): Dose-dependent, biphasic regulation of breast cancer cell line proliferation; reduction in cell motility across multiple cancer cell lines at concentrations above a threshold.

Research has shown that soy isoflavones exhibited multiple physiological activities, including antioxidant effects, bidirectional regulation of estrogen, anti-osteoporosis properties, anti-tumor effects, anti-aging effects, neuroprotective effects, regulation of cell proliferation and apoptosis, and modulation of glucose and lipid metabolism.

6. Bioavailability and Metabolism

Glycitin undergoes hydrolysis in the body, primarily through the hydrolysis of the β-glycosidic bond by colonic bacteria, resulting in the removal of the glycosyl group and the conversion to free glycitein, which can then be absorbed by the gastrointestinal mucosa.

Human intestinal bacteria transform glycitin into glycitein, which is a bioactive compound that can be absorbed into the gastrointestinal tract.

Usually, these compounds are present in glycoside form, which restrains human gastrointestinal absorption. Hence, aglycones should be obtained from isoflavone glycosides through enzymatic hydrolysis to increase the pharmacological effects and bioavailability.

A key human pharmacokinetic reference, Zhang et al. (1999), reported that glycitein is a more bioavailable soybean isoflavone than is daidzein in humans having moderate fecal isoflavone metabolism. The methoxy group at C-6 in glycitein increases lipophilicity, which may facilitate membrane permeation and contribute to this relatively higher bioavailability compared to other soy isoflavones.

Phase I metabolism studies have elaborated the metabolic fate of the compound. Glycitein is a major isoflavone of soy germ. Since data on the metabolism of glycitein are incomplete, the in vitro phase I metabolism using rat liver microsomes, human liver microsomes (HLM), as well as human fecal flora was investigated. Furthermore, the in vivo metabolism was studied after administration of glycitein to Sprague-Dawley rats. With respect to phase I metabolism, glycitein was converted to ten metabolites by liver microsomes, with 8-hydroxy(OH)-glycitein as the main metabolite.

Its bioavailability can be enhanced through microbial fermentation and advanced extraction/purification techniques.

7. Dosage Forms and Dosages Reported in the Scientific Literature

Glycitin and glycitein have appeared in the scientific literature in a variety of experimental formulations and dosages. The following reflect only dosages explicitly stated in peer-reviewed sources:

• Mouse uterotrophic assay (animal study, Song et al., 1999): Glycitein was isolated from soy germ to 99% purity. Weaning female B6D2F1 mice were dosed with glycitein at 3 mg/day in 5% Tween 80 by gavage for 4 days.
• In vitro dermal fibroblast study: Treatment with 20 μM glycitin for 24 h induced the synthesis of collagen type I and type III at both the mRNA and protein levels.
• C. elegans neuroprotection study: Transgenic C. elegans were fed with soy-derived isoflavones genistein, daidzein, and glycitein at 100 μg/ml.
• Bone marrow stem cell study (in vitro): BMSCs were induced with glycitin at concentrations of 0.01, 0.5, 1, 5, and 10 μM for 7 days.
• Human pharmacokinetic capsule study (Shinkaruk et al., 2012, Food Chemistry): Each capsule contained 8.30, 5.00, and 2.30 mg of daidzin, glycitin, and genistin, respectively. Each volunteer received 5 capsules, i.e., 87.625 mg of flavonoids total.
• Japanese randomized controlled trial (mixed isoflavones, reported in a clinical review): Taking 100 mg of isoflavone supplements per day (with 10.5% glycitein, i.e., approximately 10.5 mg glycitein per day) for a defined period was evaluated for effects on bone mineral density.
• Breast cancer cell line study (in vitro): At concentrations less than 10 mg/mL, cells responded to glycitein by increasing growth; at concentrations greater than 30 mg/mL, glycitein significantly inhibited cell growth in a dose-dependent manner. Cells treated with 60 mg/mL of glycitein did not regain normal growth after treatment was stopped.

No established therapeutic dose for isolated glycitin in humans has been defined by any regulatory body or clinical guideline, and the above should be understood strictly as experimental data from individual published studies.

8. Safety Considerations and Interactions

8.1 General Safety Profile

Systematic reviews propose a roadmap for deploying glycitein in precision nutrition, emphasizing its low toxicity. However, dedicated human safety trials specifically for glycitin or glycitin-containing supplements at high supplemental doses have not been extensively reported.

At dietary levels, these compounds are generally safe, although high-dose supplementation is discouraged in individuals with hormone-sensitive cancers.

8.2 Estrogen Receptor Activity and Hormone-Sensitive Conditions

Soy isoflavones can act as agonists, partial agonists, or antagonists to endogenous estrogens (such as estradiol) and xenoestrogens at estrogen receptors. This bidirectional estrogenic/anti-estrogenic activity has clinical implications for individuals with hormone-sensitive conditions. High-dose supplementation is discouraged in individuals with hormone-sensitive cancers.

8.3 Effects on the Male Endocrine System

Although soy isoflavones are less physiologically active than estradiol, they bind to estrogen receptor-α to exert an estrogen-like effect. In men, the consumption of soy products causes a moderate decrease in serum testosterone levels, and cases of gynecomastia and other manifestations of feminization have been reported in association with very high intakes. These effects have been documented with excessive rather than moderate consumption and are generally attributed to the isoflavone class collectively rather than to glycitin specifically.

8.4 Effect of Processing on Isoflavone Content

When compared to commercial foods, the isoflavone content was found to be 20, 2.6, 4.5, and 9.8 times lower in "homemade" soy juice, tofu, tempeh, and miso, respectively. Additionally, water soaking was found to reduce the isoflavones levels in soy-textured proteins by more than 70%. These findings mean that glycitin intake from traditional food preparations may be substantially lower than that from commercially processed soy products or standardized supplements, and that dose comparisons between dietary and supplemental glycitin exposures require careful attention to source and preparation.

8.5 Aromatase and Steroid Metabolism Interactions

In addition to estrogen receptor activity, isoflavones may also interfere with steroid metabolism by inhibiting aromatase, hydroxysteroid dehydrogenase, and steroid α-reductase. While this is documented for the isoflavone class broadly, the specific contribution of glycitein/glycitin to these enzyme interactions has not been independently quantified in human clinical studies.

8.6 Biphasic Activity at Different Concentrations

The biphasic dose-response reported in cancer cell studies — in which glycitein stimulated cell growth at low concentrations and inhibited it at high concentrations — has not been characterized in intact human clinical systems, and the implications of this biphasic pattern for supplementation are unknown.

8.7 Population-Level Intake Context

Older adults in Japan and Shanghai, China, typically consume between 25 and 50 mg/d of total isoflavones, with probably no more than 5% of these populations consuming ≥ 100 mg/d. In contrast, people in the United States and Europe consume on average less than 3 mg/d of isoflavones. Given that glycitin/glycitein accounts for approximately 5–10% of total soy isoflavones, typical dietary glycitin intakes in high-soy-consuming populations (e.g., Japan) may range from roughly 1.25 to 5 mg/day, with intakes in Western populations substantially lower.

8.8 Overall State of Evidence and Limitations

Although there have been numerous studies on the composition and biological activities of soy isoflavones, a review specifically focusing on the functional activities of glycitin is relatively limited. Therefore, a basic understanding of the structural characteristics and biological activities is crucial for the successful application of glycitin and maximizing its value.

Although there have been numerous studies on the composition and biological activities of soy isoflavones, a review specifically focusing on the functional activities of glycitin is relatively limited. The majority of studies on glycitin's biological activities have been conducted in cell culture or animal systems. Human clinical evidence at this time either does not exist for glycitin as an isolated agent, or is embedded within mixed-isoflavone studies from which glycitin's independent contribution cannot be determined. Accordingly, all proposed health effects of glycitin should be regarded as preliminary pending dedicated human trial data.

References

• ScienceDirect Topics: Glycitin — Overview (Journal of Pharmaceutical and Biomedical Analysis)
• Wikipedia: Glycitin
• Wikipedia: Glycitein
• Song TT, Hendrich S, Murphy PA. Estrogenic activity of glycitein, a soy isoflavone. J Agric Food Chem. 1999;47(4):1607–10. PubMed PMID: 10564025
• Song TT et al. Estrogenic Activity of Glycitein, a Soy Isoflavone. Journal of Agricultural and Food Chemistry, ACS Publications
• Kim YM et al. Soy Isoflavone Glycitin Promotes Human Dermal Fibroblast Cell Proliferation and Migration via TGF-β Signaling. Phytotherapy Research. 2015. PubMed PMID: 25758427
• Rüfer CE et al. In vitro and in vivo metabolism of the soy isoflavone glycitein. Mol Nutr Food Res. 2007. PubMed PMID: 17579888
• Pavese JM et al. Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kappaB/AP-1-dependent and -independent pathways. Clin Exp Metastasis. 2004. PubMed PMID: 15492830
• Gutierrez-Zepeda A et al. Soy isoflavone glycitein protects against beta amyloid-induced toxicity and oxidative stress in transgenic Caenorhabditis elegans. BMC Neurosci. 2005;6:54. PMC1215487
• Seo GY et al. TMF and glycitin act synergistically on keratinocytes and fibroblasts to promote wound healing and anti-scarring activity. Exp Mol Med. 2017. PMC5382558
• Glycitin alleviates lipopolysaccharide-induced acute lung injury via inhibiting NF-κB and MAPKs pathway activation in mice. PubMed PMID: 31306981
• The antioxidant Glycitin protects against intervertebral disc degeneration through antagonizing inflammation and oxidative stress in nucleus pulposus cells. PubMed PMID: 38019477
• Glycitin regulates osteoblasts through TGF-β or AKT signaling pathways in bone marrow stem cells. PMC5103745
• Glycitin in Soy Beans: A Mine of Their Structures, Functions, and Potential Applications. Foods. 2025. PMC12428360
• Glycitein: A comprehensive review of its bioactivities, molecular mechanisms, and therapeutic potential. Phytomedicine. 2025. ScienceDirect
• Inhibitory effects of O-methylated isoflavone glycitein on human breast cancer SKBR-3 cells. PMC4555673
• The Science of Soy: What Do We Really Know? Environ Health Perspect. 2006. PMC1480510
• Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. PMC2443803
• Secondary Hypogonadism due to Excessive Ingestion of Isoflavone in a Man. PMC9593161
• Plant-derived natural medicines for the management of osteoporosis: A comprehensive review of clinical trials. Journal of Orthopaedic Translation. 2023. ScienceDirect
• Traditional and Domestic Cooking Dramatically Reduce Estrogenic Isoflavones in Soy Foods. PMC11011382
• Phenol-Explorer: Soy and soy products isoflavone content database
• Soybean (Glycine max L.) isoflavones: Chemical composition and its chemometrics-assisted extraction and authentication. Journal of Applied Pharmaceutical Science. 2021
• Daidzein and Genistein: Natural Phytoestrogens with Potential Applications in Hormone Replacement Therapy. PMC12294992
• Glycitin Alleviates Myocardial Ischemia-reperfusion Injury By Suppressing Oxidative Stress and Apoptosis Through PI3K/Akt/NF-κB Pathway Modulation. Applied Biochemistry and Biotechnology. Springer Nature, 2026
• Shinkaruk S et al. Bioavailability of glycitein relatively to other soy isoflavones in Caucasian men. Food Chemistry. 2012. ResearchGate